| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
71,917,000 |
| Market
Cap: |
6.10(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$35.09 - $95.35 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 446 |
| Guru Rank Value : 4.5 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Protagonist Therapeutics is a clinical-stage biopharmaceutical company with various peptide-based new chemical entities in different stages of development, all derived from Co.'s proprietary technology platform. Co.'s clinical programs address two main categories of diseases; hematology and blood disorders, and inflammatory and immunomodulatory diseases. Co.'s main clinical asset, rusfertide (generic name for PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of erythrocytosis, iron overload and other blood disorders. PN-943 is an investigational, orally delivered, gut-restricted alpha-4-beta-7 specific integrin antagonist for inflammatory bowel disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
55,252 |
85,667 |
169,226 |
599,446 |
| Total Sell Value |
$4,563,395 |
$6,607,409 |
$11,115,236 |
$28,605,786 |
| Total People Sold |
3 |
4 |
4 |
5 |
| Total Sell Transactions |
4 |
8 |
16 |
36 |
| End Date |
2025-10-25 |
2025-07-24 |
2025-01-23 |
2024-01-24 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Molina Arturo Md |
Chief Medical Officer |
• – – |
2026-01-20 |
4 |
S |
$82.48 |
$784,715 |
D/D |
(9,514) |
97,266 |
|
-1% |
|
| Ali Asif |
Chief Financial Officer |
• – – |
2026-01-20 |
4 |
S |
$82.48 |
$708,338 |
D/D |
(8,588) |
78,077 |
|
-1% |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2026-01-20 |
4 |
S |
$82.48 |
$2,840,446 |
D/D |
(34,438) |
580,505 |
|
-1% |
|
| Selick Harold E |
Director |
– • – |
2026-01-09 |
4 |
OE |
$4.21 |
$60,199 |
D/D |
14,299 |
60,845 |
|
- |
|
| Giraudo Bryan |
Director |
– • – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,695 |
17,825 |
|
- |
|
| Odowd Sarah A |
Director |
– • – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,695 |
7,825 |
|
- |
|
| Selick Harold E |
Director |
– • – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,695 |
46,546 |
|
- |
|
| Molina Arturo Md |
Chief Medical Officer |
• – – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
25,600 |
106,780 |
|
- |
|
| Ali Asif |
Chief Financial Officer |
• – – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
25,600 |
86,665 |
|
- |
|
| Waddill William D. |
Director |
– • – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,695 |
7,825 |
|
- |
|
| Williams Lewis T |
Director |
– • – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,695 |
7,825 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
95,400 |
614,943 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2025-11-21 |
4 |
GD |
$0.00 |
$0 |
D/D |
440 |
519,543 |
|
- |
|
| Molina Arturo Md |
Chief Medical Officer |
• – – |
2025-11-17 |
4 |
S |
$84.77 |
$229,896 |
D/D |
(2,712) |
81,180 |
|
1% |
|
| Waddill William D. |
Director |
– • – |
2025-10-10 |
4 |
AS |
$69.25 |
$979,480 |
D/D |
(12,000) |
5,130 |
|
-6% |
|
| Waddill William D. |
Director |
– • – |
2025-10-10 |
4 |
OE |
$6.98 |
$83,760 |
D/D |
12,000 |
17,130 |
|
- |
|
| Waddill William D. |
Director |
– • – |
2025-09-22 |
4 |
AS |
$64.25 |
$257,000 |
D/D |
(4,000) |
5,130 |
|
27% |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2025-09-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
620 |
519,983 |
|
- |
|
| Waddill William D. |
Director |
– • – |
2025-08-27 |
4 |
AS |
$59.25 |
$237,000 |
D/D |
(4,000) |
9,130 |
|
34% |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2025-07-25 |
4 |
S |
$54.78 |
$570,534 |
D/D |
(10,415) |
520,603 |
|
-53% |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2025-07-23 |
4 |
S |
$54.79 |
$959,921 |
D/D |
(17,520) |
531,018 |
|
-66% |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2025-07-22 |
4 |
S |
$55.05 |
$1,214,678 |
D/D |
(22,065) |
548,538 |
|
-64% |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2025-07-21 |
4 |
S |
$54.86 |
$705,445 |
D/D |
(12,859) |
570,603 |
|
-63% |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2025-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
583,462 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2025-07-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,000 |
558,462 |
|
- |
|
237 Records found
|
|
Page 1 of 10 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.90 (1.07%) 
